Panacea Biotec share price & results
- Jun 2026
- Sept 2026
Vaccine and pharma formulations maker with a growing nutrition/baby-care line; exports to 50+ countries.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 200 | +19.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 2.8 | +3.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.2 | −44.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | -1.91 | +3.1 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -5.78 | +7.8 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 10.26 | +14.5 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −30.4% 1Y
1Y: ₹440.8 on 24 Oct 2025 → ₹306.75. High ₹607.75 (9 Jun 2026), low ₹296.05 (30 Mar 2026).
- Previous close
- ₹311.45
- Market cap
- ₹1.9k Cr
- 52-week range
- ₹296.05 – ₹607.75
- One year
- −30.09%
- Return on equity (TTM to Jun 2026)
- -1.91%
Overview
- Symbol
- NSE:PANACEABIO
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Panacea Biotec Limited does
Based on the company's own presentations, annual report and earnings calls.
Panacea Biotec is a biotechnology company that researches, manufactures and markets paediatric combination vaccines - its legacy business - alongside pharmaceutical formulations focused on organ transplantation, oncology and diabetes management, plus a newer nutrition and baby-care line. It earns by selling vaccines to government immunisation programmes and UN agencies (UNICEF, PAHO) as well as the private paediatric market in India and abroad, while pharmaceutical formulations are sold domestically (through subsidiary Panacea Biotec Pharma) and exported to regulated markets (US, Canada, Europe) and emerging markets. Manufacturing is backward-integrated from in-house vaccine drug-substance production through to finished-dose vaccines and formulations at its Punjab and Himachal Pradesh facilities. It has more recently expanded into nutrition and hygiene products sold under its own brands through retail and e-commerce.
Segments
- Vaccines
- Pharmaceutical Formulations
- Nutrition & Baby Care
- Manufacturing facilities
- 2 integrated plants - Baddi (Himachal Pradesh) and Lalru (Punjab), covering drug-substance, vaccine and formulation manufacturing
- Regulatory approvals for facilities
- Cleared by USFDA, WHO PQ, EMA, ANVISA and Australia TGA, among others
- R&D professionals
- 150+
- Countries vaccines exported to
- ~30 (Africa, Asia, Latin America)
- Countries pharmaceuticals/nutrition products exported to
- ~40 (incl. US, Canada, Germany, Gulf, Africa, Asia, Latin America)
- Vaccine registrations by country
- 16 countries registered, with a pathway to ~29 African markets via AMRH
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −44% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| Expenses | 140 | 156 | 159 | 168 | 159 | 153 | 164 | 194 |
| Operating profit | 7 | 8 | -27 | -1 | -18 | 12 | 3 | 6 |
| Operating margin | 4.8% | 4.9% | −20.3% | −0.7% | −12.6% | 7.1% | 1.5% | 2.8% |
| Other income | 7 | 6 | 36 | 17 | 9 | 5 | 5 | 7 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 |
| Depreciation | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before tax | 5 | 4 | -0 | 7 | -19 | 6 | -1 | 4 |
| Tax rate | 1.1% | −1.4% | 4875.0% | 39.6% | −26.9% | 40.1% | −20.0% | 38.4% |
| Net profit | 5 | 4 | -2 | 4 | -14 | 4 | -1 | 2 |
| EPS (₹ per share) | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 460 | 559 | 559 | 640 |
| Expenses | 558 | 579 | 585 | 644 |
| Operating profit | -98 | -20 | -26 | -5 |
| Other income | 154 | 62 | 57 | 36 |
| Interest | 4 | 4 | 4 | 6 |
| Depreciation | 39 | 37 | 35 | 33 |
| Profit before tax | 12 | 1 | -8 | -7 |
| Net profit | -33 | -1 | -9 | -7 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 871 | 837 | 836 | 829 | 820 | 829 |
| Borrowings | 34 | 20 | 21 | 22 | 23 | 24 |
| Other liabilities | 848 | 407 | 378 | 433 | 405 | 404 |
| Total liabilities | 1,759 | 1,271 | 1,241 | 1,290 | 1,254 | 1,262 |
| Fixed assets | 622 | 600 | 582 | 567 | 594 | 576 |
| Capital work in progress | 17 | 42 | 102 | 128 | 110 | 144 |
| Investments | 5 | 13 | 40 | 3 | 3 | 10 |
| Other assets | 1,114 | 615 | 517 | 592 | 547 | 532 |
| Total assets | 1,759 | 1,271 | 1,241 | 1,290 | 1,254 | 1,262 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 107 | -108 | -422 | 0 | -27 | 17 |
| Cash from investing | -48 | 1,283 | 430 | 10 | 65 | -40 |
| Cash from financing | -47 | -1,176 | -18 | -3 | -3 | -1 |
| Net cash flow | 12 | -2 | -10 | 7 | 35 | -25 |
| Free cash flow | 89 | -119 | -424 | -71 | -77 | -37 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 49 | 45 | 48 | 37 | 47 | 42 |
| Inventory days | 311 | 296 | 292 | 282 | 391 | 251 |
| Days payable | 440 | 327 | 256 | 244 | 413 | 247 |
| Cash conversion cycle | -80 | 14 | 83 | 76 | 25 | 46 |
| Working capital days | -43 | -229 | -5 | -2 | 65 | 51 |
| Return on capital employed | 5.0% | −6.0% | −10.0% | −4.0% | −5.0% | −2.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
Vaccines contributes 67.5% of reported segment revenue.
Quarter ended 30 Jun 2026 · Consolidated
- Vaccines 67.5%
₹134.67 crore
- Formulations 32.5%
₹64.90 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Vaccines | 134.67 | 67.5% |
| Formulations | 64.90 | 32.5% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹199.57 crore
- Intersegment adjustment
- ₹0.00 crore
- Net segment revenue
- ₹199.57 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
How the mix has moved
Vaccines grew from 63% to 67% of revenue over the last two years.
| Segment | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Jun 2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Vaccines | 63% | 49% | 52% | 66% | 51% | 67% | 60% | 67% | +20.0% |
| Formulations | — | 51% | 48% | 34% | 49% | 33% | 40% | 33% | +19.2% |
Share of reported segment revenue by quarter, consolidated basis, as filed. A quarter the company did not report is left blank, never carried forward.
See how segments are shifting across companies → Segment Shift
Ownership
Who owns it
Promoters hold 72.48% as of Sept 2026; institutions added 0.66 pts since Jun 2026.
- Promoters 72.48%
- Foreign institutions 2.75%
- Domestic institutions 2.47%
- Public 22.31%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Endowment +0.10 pp 1.81% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Panacea Biotec Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 49.01% | unchanged | |
| 15.27% | unchanged | |
| 4.10% | unchanged | |
| 3.68% | unchanged | |
| Endowment | 1.81% | +0.10 pp |
| 1.47% | unchanged | |
| 0.33% | unchanged | |
| 0.09% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Panacea Biotec Limited
Free account: one company. Everything above stays public.
Write why you follow Panacea Biotec Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Panacea Biotec Limited
Guides on how to read this kind of business and the numbers that matter.